Patients who are receiving any other concurrent investigational therapy, or who have received investigational therapy within  days of the first scheduled day of protocol treatment (investigational therapy as defined as treatment for which there is currently no regulatory authority approved indication) will not be eligible
Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy
Current use or history of receiving a non-approved, investigational treatment within  days prior to cycle  day  of protocol therapy
Treatment with any investigational agent or approved therapy within  days
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within a period of  half-lives of the investigational therapy in question prior to the day of dosing with the PEGylated AuroShell particles (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Investigational therapy, defined as any drug that has not been approved for marketing for any indication in cGVHD will be restricted from the study
Treatment with a non-approved or investigational drug within  days prior to day  of study treatment
Has used any investigational drug (including marketed drugs not approved for this indication) ?  days of CD. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved, returned to baseline or stabilized.
Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment
Treatment with a non-approved or investigational drug within  days of study treatment
Receiving concurrent anti-cancer treatment (excluding radiation therapy), either approved or investigational
Treatment with a non-approved or investigational drug within  days of study treatment
Treatment with an approved or investigational chemotherapy drug within  days of Day 
Treatment with an approved or investigational anti-CD drug within  days of Day 
Treatment with an approved or investigational biologic drug that does not target CD within  days of Day 
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within  days of IPHC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within  days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Have discontinued investigational product or non approved use of a drug or device from a clinical trial within  days before the first day of study treatment.
Prior or concurrent exposure to any of the following: approved or investigational treatments for SMM or/and multiple myeloma, daratumumab or other anti CD- therapies, treatment with corticosteroids with a dose greater than (>)  milligram (mg) prednisone per day or equivalent and bone-protecting agents (eg, bisphosphonates, denosumab) or are only allowed if given in a stable dose and for a nonmalignant condition, or received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within  weeks before Cycle , Day 
Treatment with a non-approved or investigational drug within  days before day  of study treatment
Use of any investigational drug (including marketed drugs not approved for this indication) within  days prior to the first dose of study drug
Chemotherapy (approved or investigational) within  weeks prior to the first day of treatment or antibody therapy within  weeks prior to the first day of treatment
Chemotherapy (approved or investigational) within  weeks prior to signing consent
Treatment with other investigational agents (defined as not used in accordance with the approved indication) within  weeks of Day 
Treatment with a non-approved or investigational drug within  days before visit 
Is receiving concurrent standard and/or investigational anti-cancer therapy or has received such therapy within a period of  days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication); or
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within  days of the first scheduled day of protocol treatment (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Treatment with a non-approved or investigational drug or agent within  days before day  of trial treatment
Patients who have received any investigational drug within  days prior to Day  of study entry (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Treatment with a non-approved or investigational drug within  days prior to day  of study treatment
Use of any investigational drug (including marketed drugs not approved for this indication) within  weeks prior to screening. No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved or returned to baseline
Treatment with approved or investigational cancer therapy within  days prior to treatment initiation
Prior treatment with an investigational or approved agent for the purpose of inhibiting HER family members
Patients who are receiving concurrent investigational therapy or who have received investigational therapy within  days of the first scheduled day of protocol treatment* (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Ipilimumab-treated patients must be receiving treatment for the indication(s)\n             approved in their country of residence or where they are receiving treatment
Treatment with other investigational agents (defined as not used in accordance with the approved indication) within  weeks of Day 
